+

US20060094702A1 - 5-HT4 receptor antagonists - Google Patents

5-HT4 receptor antagonists Download PDF

Info

Publication number
US20060094702A1
US20060094702A1 US11/304,110 US30411005A US2006094702A1 US 20060094702 A1 US20060094702 A1 US 20060094702A1 US 30411005 A US30411005 A US 30411005A US 2006094702 A1 US2006094702 A1 US 2006094702A1
Authority
US
United States
Prior art keywords
alkyl
hydrogen
halo
formula
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/304,110
Inventor
Francis King
Laramie Gaster
Keith Mulholland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Priority to US11/304,110 priority Critical patent/US20060094702A1/en
Publication of US20060094702A1 publication Critical patent/US20060094702A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Definitions

  • This invention relates to novel compounds having pharmacological activity, to a process for their preparation and to their use as pharmaceuticals.
  • WO 91/16045 (SmithKline and French Laboratories Limited) describes the use of cardiac 5-HT 4 receptor antagonists in the treatment of atrial arrhythmias and stroke.
  • EP-A-501322 (Glaxo Group Limited), WO 93/02677, WO 93/03725, WO 93/05038, WO 93/05040, WO 93/18036, PCT/EP93/03054, PCT/GB93/01895, PCT/GB93/02028, PCT/EP93/02808, PCT/EP93/02775, PCT/EP93/02809, PCT/GB93/02130, PCT/EP93/003054, PCT/GB94/000172 (SmithKline Beecham plc) describe compounds having 5-HT 4 receptor antagonist activity.
  • the present invention provides a compounds of formula (I) and pharmaceutically acceptable salts thereof, and the use of a compound of formula (1) or a pharmaceutically acceptable salt thereof: X—CO—CH 2 -Z (I)
  • alkyl or alkyl containing groups include C 1 , C 2 , C 3 , C 4 , C 5 , C 6 , C 7 , C 8 , C 9 , C 10 , C 11 or C 12 branched, straight chained or cyclic alkyl, as appropriate.
  • C 1-4 alkyl groups include methyl, ethyl, n- and iso-propyl, n-, iso-, sec- and tert-butyl.
  • Cyclic alkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl optionally substituted by one of more alkyl groups of up to 4 carbon atoms.
  • Aryl includes phenyl and naphthyl optionally substituted by one or more substituents selected from halo, C 1-6 alkyl and C 1-6 alkoxy.
  • Values for monocyclic heteroaryl include pyridyl, pyrimidyl, pyrazinyl, pyrryl, imidazolyl, thienyl, furanyl, oxazole or thiazole (all possible isomers).
  • Bicyclic heteroaryl include benzofuranyl, benzothiophenyl, indolyl and indazolyl, quinolyl and isoquinolyl (all possible isomers).
  • Values for 3 to 8 membered heterocyclyl include cyclic polymethylene interrupted by one or two of N, O or S, linked through C or N, for example N-linked piperidinyl or pyrrolidinyl.
  • a substituent when halo is selected from fluoro, chloro, bromo and iodo.
  • Suitable examples of the X 1 —(CH 2 ) x —X 2 moiety include O—(CH 2 ) 2 —O, O—(CH 2 ) 3 —O, O—CH 2 —O, O—(CH 2 ) 2 —NR, O—(CH 2 ) 2 —S or O—CH 2 —CONR, wherein any of the methylene linkages are optionally mono- or di- substituted by C 1-6 alkyl groups, such as methyl.
  • X 1 —(CH 2 ) 2 —X 2 is O—(CH 2 ) 2 —O.
  • X 1 —(CH 2 ) x —X 2 include O—(CH 2 ) 2 —CH 2 , O—(CH 2 ) 3 —CH 2 , O—CH 2 —CH 2 , or corresponding values wherein X 1 ⁇ X 2 ⁇ CH 2 , wherein any of the methylene linkages are optionally mono- or di-substituted by C 1-6 alkyl groups, such as methyl.
  • X 1 —(CH 2 ) 2 —X 2 is O—(CH 2 ) 2 —CH 2 .
  • Suitable examples of X 6 -X 7 when CR 1 f R 2 f —CR 3 f R 4 f include CH 2 —CH 2 and CH ⁇ CH.
  • X 6 —X 7 is preferably NR z —CO, however, such as NH—CO or NEt-CO.
  • Values for A include —CH 2 —(CH 2 ) r —CH 2 — wherein r is 0, 1 or 2; —CH 2 —CH ⁇ CH—; —C(CH 3 ) ⁇ CH— or when Xg is CH or N, A may be —(CH 2 ) 2 —CH ⁇ or —CH ⁇ CH—CH ⁇ .
  • Other examples of A are as described in the aforementioned patent publications.
  • R 1 g and R 2 g are often hydrogen or R 1 g and R 2 9 are gem-dimethyl. r is often 1.
  • R 3 g is preferably hydrogen.
  • R 4 g is preferably hydrogen or halo, such as fluoro.
  • n 1 is preferably 2, 3 or 4 when the azacycle is attached at the nitrogen atom and n1 is preferably 1 when the azacycle is attached at a carbon atom, such as the 4-position when q is 2.
  • n 2 is preferably such that the number of carbon atoms between the ester or amide linkage is from 2 to 4 carbon atoms.
  • n 3 is preferably 2, 3 or 4.
  • R 8 and R 9 are preferably both alkyl, especially one of R 8 and R 9 is C 4 larger alkyl.
  • the invention also provides novel compounds within formula (I) with side chains (i), (ii), (iii), (iv), (v), (vi) or (vii).
  • the piperidine ring in (i), (ii) or (iii) may be replaced by pyrrolidinyl or azetidinyl, and/or the N-substituent in (i) or (ii) may be replaced by C 3 or larger alkyl or optionally substituted benzyl.
  • N-substituent in formula (i) or (ii) may be replaced by (CH 2 ) n R 4 as defined in formula (I) of EPA 501322 and in relation to the specific examples of EP-A-501322, or it may be replaced by a substituent as as defined in formula (I) and in relation to the specific examples of in PCT/EP93/03054 (SmithKline Beecham plc).
  • the pharmaceutically acceptable salts of the compounds of the formula (I) include acid addition salts with conventional acids such as hydrochloric, hydrobromic, boric, phosphoric, sulphuric acids and pharmaceutically acceptable organic acids such as acetic, tartaric, maleic, citric, succinic, benzoic, ascorbic, methanesulphonic, a-keto glutaric, a-glycerophosphoric, and glucose-1-phosphoric acids.
  • conventional acids such as hydrochloric, hydrobromic, boric, phosphoric, sulphuric acids
  • pharmaceutically acceptable organic acids such as acetic, tartaric, maleic, citric, succinic, benzoic, ascorbic, methanesulphonic, a-keto glutaric, a-glycerophosphoric, and glucose-1-phosphoric acids.
  • Examples of pharmaceutically acceptable salts include quaternary derivatives of the compounds of formula (I) such as the compounds quaternised by compounds R x -T wherein R x is C 1-6 alkyl, phenyl-C 1-6 alkyl or C 5-7 cycloalkyl, and T is a radical corresponding to an anion of an acid.
  • R x include methyl, ethyl and n- and iso-propyl; and benzyl and phenethyl.
  • Suitable examples of T include halide such as chloride, bromide and iodide.
  • Examples of pharmaceutically acceptable salts also include internal salts such as N-oxides.
  • the compounds of the formula (I), their pharmaceutically acceptable salts, (including quaternary derivatives and N-oxides) may also form pharmaceutically acceptable solvates, such as hydrates, which are included wherever a compound of formula (I) or a salt thereof is herein referred to.
  • the compounds of formula (I) may be prepared by conventional methods for forming ketones, such as those described in EP-A-242973 (Glaxo Group Limited) and EP-A-387431 (Beecham Group plc).
  • the compounds of the present invention are 5-HT 4 receptor antagonists and it is thus believed may generally be used in the treatment or prophylaxis of gastrointestinal disorders, cardiovascular disorders and CNS disorders.
  • IBS irritable bowel syndrome
  • these compounds block the ability of 5-HT to stimulate gut motility via activation of enteric neurones. In animal models of IBS, this can be conveniently measured as a reduction of the rate of defaecation. They are also of potential use in the treatment of urinary incontinence which is often associated with IBS.
  • They may also be of potential use in other gastrointestinal disorders, such as those associated with upper gut motility, and as antiemetics. In particular, they are of potential use in the treatment of the nausea and gastric symptoms of gastro-esophageal reflux disease and dyspepsia. Antiemetic activity is determined in known animal models of cytotoxic-agent/radiation induced emesis.
  • Anxiolytic activity is likely to be effected via the hippocampus (Dumuis et al 1988, Mol Pharmacol., 34, 880-887). Activity can be demonstrated in standard animal models, the social interaction test and the X-maze test.
  • Migraine sufferers often undergo situations of anxiety and emotional stress that precede the appearance of headache (Sachs, 1985, Migraine, Pan Books, London). It has also been observed that during and within 48 hours of a migraine attack, cyclic AMP levels are considerably increased in the cerebrospinal fluid (Welch et al., 1976, Headache 16, 160-167). It is believed that a migraine, including the prodomal phase and the associated increased levels of cyclic AMP are related to stimulation of 5-HT 4 receptors, and hence that administration of a 5-HT 4 antagonist is of potential benefit in relieving a migraine attack.
  • CNS disorders of interest include schizophrenia, Parkinson's disease and Huntingdon's chorea.
  • the invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • compositions are prepared by admixture and are usually adapted for enteral such as oral, nasal or rectal, or parenteral administration, and as such may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, nasal sprays, suppositories, injectable and infusable solutions or suspensions.
  • enteral such as oral, nasal or rectal, or parenteral administration
  • enteral such as oral, nasal or rectal, or parenteral administration
  • enteral such as oral, nasal or rectal, or parenteral administration
  • enteral such as oral, nasal or rectal, or parenteral administration
  • enteral such as oral, nasal or rectal, or parenteral administration
  • enteral such as oral, nasal or rectal, or parenteral administration
  • enteral such as oral, nasal or rectal, or parenteral administration
  • oral liquid preparations powders, granules, lozenges, reconstitutable powders, nasal sprays, s
  • Tablets and capsules for oral administration are usually presented in a unit dose, and contain conventional excipients such as binding agents, fillers, diluents, tabletting agents, lubricants, disintegrants, colourants, flavourings, and wetting agents.
  • the tablets may be coated according to well known methods in the art, for example with an enteric coating.
  • Suitable fillers for use include cellulose, mannitol, lactose and other similar agents.
  • Suitable disintegrants include starch, polyvinylpolypyrrolidone and starch derivatives such as sodium starch glycollate.
  • Suitable lubricants include, for example, magnesium stearate.
  • Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulphate.
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.
  • suspending agents for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or
  • Oral liquid preparations are usually in the form of aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs or are presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and flavouring or colouring agents.
  • the oral compositions may be prepared by conventional methods of blending, filling or tabletting. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are, of course, conventional in the art.
  • fluid unit dose forms are prepared containing a compound of the present invention and a sterile vehicle.
  • the compound depending on the vehicle and the concentration, can be either suspended or dissolved.
  • Parenteral solutions are normally prepared by dissolving the compound in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing.
  • adjuvants such as a local anaesthetic, preservatives and buffering agents are also dissolved in the vehicle.
  • the composition can be frozen after filling into the vial and the water removed under vacuum.
  • Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilised by exposure of ethylene oxide before suspending in the sterile vehicle.
  • a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound of the invention.
  • the invention further provides a method of treatment or prophylaxis of irritable bowel syndrome, dyspepsia, atrial arrhythmias and stroke, anxiety and/or migraine in mammals, such as humans, which comprises the administration of an effective amount of a compound of the formula (I) or a pharmaceutically acceptable salt thereof.
  • a unit dose for a 70 kg adult will normally contain 0.05 to 1000 mg for example 0.5 to 500 mg, of the compound of the invention.
  • Unit doses may be administered once or more than once a day, for example, 2, 3 or 4 times a day, more usually 1 to 3 times a day, that is in the range of approximately 0.0001 to 50 mg/kg/day, more usually 0.0002 to 25 mg/kg/day.
  • the invention also provides a compound of formula (1) or a pharmaceutically acceptable salt thereof for use as an active therapeutic substance, in particular for use in the treatment of irritable bowel syndrome, gastro-oesophageal reflux disease, dyspepsia, atrial arrhythmias and stroke, anxiety and/or migraine.
  • a preferred compound corresponds to any example, but wherein there is an amino substituent in the 4-position and a chloro substituent in the 5-position of the benzoic acid nucleus depicted in formula (I).
  • reaction mixture After a further 1 h, at ⁇ 78° C., the reaction mixture was allowed to warm to room temperature, whereupon the reaction mixture was quenched with aq. ammonium chloride. The reaction mixture was then partitioned between ethyl acetate and water. The aqueous layer was then extracted with ethyl acetate (1 ⁇ ), and the combined organic layers were dried (Na 2 SO 4 ), and evaporated under reduced pressure to give a pale brown solid, which was purified by silica-gel chromatography (CH 2 Cl 2 /5%MeOH as eluant) to give the title compound as an off white solid (0.246 g, 31%).
  • the product from b) (0.99 g, 3.81 mmol) was dissolved in dry THF, cooled to 0° C., and treated with 3.0M methylmagnesium bromide in diethyl ether (1.41 ml, 4.24 mmol) under argon, with stirring. After 20 minutes at 0° C., the reaction mixture was allowed to warm to room temperature, and after 2 h, a further quantity of 3.0M methylmagnesium bromide (1.41 ml, 4.24 mmol) was added. The reaction mixture was then stirred for a further 2 h, before aq. ammonium chloride was added. The reaction mixture was then partitioned between EtOAc and water.
  • guinea-pigs Male guinea-pigs, weighing 250-400 g are used. Longitudinal muscle-myenteric plexus preparations, approximately 3 cm long, are obtained from the distal colon region. These are suspended under a 0.5 g load in isolated tissue baths containing Krebs solution bubbled with 5% CO 2 in O 2 and maintained at 37° C. In all experiments, the Krebs solution also contains methiothepin 10-7M and granisetron 10-6M to block effects at 5-HT 1 , 5-HT 2 and 5-HT 3 receptors.
  • a concentration of 5-HT is selected so as to obtain a contraction of the muscle approximately 40-70% maximum(10-9M approx).
  • the tissue is then alternately dosed every 15 min with this concentration of 5-HT and then with an approximately equi-effective concentration of the nicotine receptor stimulant, dimethylphenylpiperazinium (DMPP).
  • DMPP dimethylphenylpiperazinium
  • increasing concentrations of a putative 5-HT 4 receptor antagonist are then added to the bathing solution.
  • the effects of this compound are then determined as a percentage reduction of the contractions evoked by 5-HT or by DMPP. From this data, pIC 50 values are determined, being defined as the -log concentration of antagonist which reduces the contraction by 50%.
  • a compound which reduces the response to 5-HT but not to DMPP is believed to act as a 5-HT 4 receptor antagonist.
  • the compound of Example 1 had a pIC 50 of 6.8.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Compounds of formula (I) and pharmaceutically acceptable salts thereof, and the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof:
X—CO—CH2-Z wherein X is a monocyclic or polycyclic aromatic group,
Z is of sub-formula (h), (j) or (k):
Figure US20060094702A1-20060504-C00001
 wherein
  • n1 is 1, 2, 3 or 4; n2 is 0, 1, 2, 3 or 4; n3is 2, 3, 4 or 5; q is 0, 1, 2 or 3; p is 0, 1 or 2; m is 0, 1 or 2;
  • R5 is hydrogen, C1-2 alkyl, aralkyl or R5 is (CH2)z-R10 wherein z is 2 or 3 and R10 is selected from cyano, hydroxyl, C1-6 alkoxy, phenoxy, C(O)C1-6 alkyl, COC6H5, —CONR11R12, NR11COR12, SO2NR11R12 or NR11SO2R12 wherein R11 and R12 are hydrogen or C1-6 alkyl; or R5 is straight or branched chain alkylene of chain length 1-6 carbon atoms terminally substituted by aryl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 5 or 6 membered monocyclic heteroaryl or 9 or 10 membered fused bicyclic heteroaryl linked through carbon, C2-7 alkoxycarbonyl, or secondary or tertiary hydroxy substituted C1-6 alkyl; ; and
  • R6, R7 and R8 are independently hydrogen or C1-6 alkyl; and R9 is hydrogen or C1-10alkyl; and their use as pharmaceuticals in the treatment of gastrointestinal disorders, cardiovascular disorders and CNS disorders.

Description

  • This is a continuation of application Ser. No. 10/317,159 filed Dec. 11, 2002 (pending) which is a continuation of application Ser. No. 09/939,914 filed Aug. 27, 2001(abandoned), application Ser. No. 09/013,135 filed Jan. 26, 1998 (abandoned), which is a continued prosecution application of Application Ser. No. 09/013,135 filed Dec. 1, 2000, which is a continued prosecution application of application Ser. No. 09/013,135 filed Feb. 24, 2000, which is a divisional application of application Ser. No. 08/553,390 filed Nov. 22, 1995 U.S. Pat. No. 5,741,801, which is a 371 of International Application No. PCT/EP94/01583 filed May 16, 1994, which claims benefit from foreign application GB 9310582.3 filed May 22, 1993.
  • This invention relates to novel compounds having pharmacological activity, to a process for their preparation and to their use as pharmaceuticals.
  • European Journal of Pharmacology 146 (1988), 187-188, and Naunyn-Schmiedeberg's Arch. Pharmacol. (1989) 340:403-410, describe a non classical 5-hydroxytryptamine receptor, now designated the 5-HT4 receptor, and that ICS 205-930, which is also a 5-HT3 receptor antagonist, acts as an antagonist at this receptor.
  • WO 91/16045 (SmithKline and French Laboratories Limited) describes the use of cardiac 5-HT4 receptor antagonists in the treatment of atrial arrhythmias and stroke.
  • EP-A-501322 (Glaxo Group Limited), WO 93/02677, WO 93/03725, WO 93/05038, WO 93/05040, WO 93/18036, PCT/EP93/03054, PCT/GB93/01895, PCT/GB93/02028, PCT/EP93/02808, PCT/EP93/02775, PCT/EP93/02809, PCT/GB93/02130, PCT/EP93/003054, PCT/GB94/000172 (SmithKline Beecham plc) describe compounds having 5-HT4 receptor antagonist activity.
  • It has now been discovered that certain novel compounds also have 5-HT4 receptor antagonist properties.
  • Accordingly, the present invention provides a compounds of formula (I) and pharmaceutically acceptable salts thereof, and the use of a compound of formula (1) or a pharmaceutically acceptable salt thereof:
    X—CO—CH2-Z   (I)
    • X is a monocyclic or polycyclic aromatic group, such as a group of formula (a), (b),
      Figure US20060094702A1-20060504-C00002
      wherein
    • L is N or CRS wherein RS is hydrogen, C1-6 alkoxy, halogen, C1-4 alkyl or cyano;
    • Q is NR1 a, CH2, O or S;
    • W is CH or N;
    • X1—(CH2)x—X2 forms a 5-7 membered ring wherein X1 is O or S; X2 is O, S, —CH2—, NR or NRCO wherein R is hydrogen or C1-6 alkyl; and
    • x is 1, 2 or 3;
    • one of X3 and X4 is N and the other is C; and
    • X5 is N or CR1 wherein R1 is hydrogen, C1-6 alkoxy, halo, C1-6 alkyl or cyano;
    • R1 a is hydrogen, C1-10 alkyl, C2-6 alkenyl, aralkyl, C2-6 alkanoyl or C2-6 alkanoyl C1-3 alkyl;
    • R3 a is hydrogen, halo, C1-6 alkyl, amino, nitro or C1-6 alkoxy;
    • R4 a is hydrogen, halo, C1-6 alkyl or C1-6 alkoxy;
    • R1 b is C1-6 alkoxy; and
    • R2 b is hydrogen, chloro or fluoro;
    • R3 b is hydrogen, C1-6 alkyl, amino optionally substituted by a C1-6 alkyl group, halo, hydroxy or C1-6 alkoxy;
    • R4 b is hydrogen, halo, C1-6 alkyl, C1-6 alkoxy, nitro, amino or C1-6 alkylthio; and
    • R5 b is hydrogen, halo, C1-6 alkyl, C1-6 alkoxy or amino;
    • Rc is hydrogen, C1-6 alkoxy, halo or C1-6 alkyl;
    • R1 d is hydrogen, amino, halo, C1-6 alkyl, hydroxy or C1-6 alkoxy;
    • R2d is hydrogen, halo, C1-6 alkyl, C1-6 alkoxy, nitro, amino or C1-6 alkylthio;
    • R3 d is hydrogen, halo, C1-6 alkyl, C1-6 alkoxy or amino;
    • R4 d and R5 d are independently hydrogen or C1-6 alkyl;
    • R1 e is hydrogen, halogen, CF3, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, C1-6 alkylsulphonyl, C1-6 alkylsulphinyl, C1-7 acyl, cyano, C1-6 alkoxycarbonyl, C1-7 acylamino, hydroxy, nitro or amino, aminocarbonyl, or aminosulphonyl, optionally N-substituted by one or two groups selected from C1-6 alkyl, C3-8 cycloalkyl, and C3-8 cycloalkyl C1-4 alkyl or disubstituted by C4 or C5 polymethylene; phenyl or phenyl C1-4 alkyl group optionally substituted in the phenyl ring by one or two of halogen, C1-6 alkoxy or C1-6 alkyl groups;
    • R3 e is hydrogen, halo, C1-6 alkyl, amino, nitro or C1-6 alkyl;
    • R4 e is hydrogen, halo, C1-6 alkyl or C1-6 alkoxy;
    • X6-X7 is NRz—CO or CR1 fR2 f—CR3 fR4 f where
    • Rz and R1 f to R4 f are independently hydrogen or C1-6 alkyl; and/or
    • R1 f/R2 f and R3 f/R4 f together are a bond and/or R1 f/R2 f/R3 f/R4 f are joined to form C3-6 polymethylene;
    • Ra f is hydrogen, halo, C1-6 alkyl, amino, nitro or C1-6 alkyl;
    • Rb f is hydrogen, halo, C1-6 alkyl or C1-6 alkoxy;
    • Xg is O, S, SO, SO2, CH2, CH, N or NR wherein R is hydrogen or C1-6 alkyl;
    • A is a saturated or unsaturated polymethylene chain of 2-4 carbon atoms;
    • R1 g and R2 g are hydrogen or C1-6 alkyl;
    • R3 g is hydrogen, halo, C1-6 alkyl, amino, nitro or C1-6 alkoxy;
    • R4 g is hydrogen, halo, C1-6 alkyl or C1-6 alkoxy;
    • Z is of sub-formula (h), (j) or (k):
      Figure US20060094702A1-20060504-C00003
      wherein
    • n1 is 1, 2, 3 or 4; n2 is 0, 1, 2, 3 or 4; n3 is 2, 3, 4 or 5;
    • q is 0, 1, 2 or 3; p is 0, 1 or 2; m is 0, 1 or 2;
    • R5 is hydrogen, C1-12 alkyl, aralkyl or R5 is (CH2)z-R10 wherein z is 2 or 3 and R10 is selected from cyano, hydroxyl, C1-6 alkoxy, phenoxy, C(O)C1-6 alkyl, COC6H5, —CONR11R12, NR11COR12, SO2NR11R12 or NR11SO2R12 wherein R11 and R12 are hydrogen or C1-6 alkyl; or R5 is straight or branched chain alkylene of chain length 1-6 carbon atoms terminally substituted by aryl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 5 or 6 membered monocyclic heteroaryl or 9 or 10 membered fused bicyclic heteroaryl linked through carbon, C2-7 alkoxycarbonyl, or secondary or tertiary hydroxy substituted C1-6 alkyl; ; and
    • R6, R7 and R8 are independently hydrogen or C1-6 alkyl; and
    • R9 is hydrogen or C1-10 alkyl; having 5-HT4 receptor antagonist activity.
  • Examples of alkyl or alkyl containing groups include C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C 11 or C12 branched, straight chained or cyclic alkyl, as appropriate. C1-4 alkyl groups include methyl, ethyl, n- and iso-propyl, n-, iso-, sec- and tert-butyl. Cyclic alkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl optionally substituted by one of more alkyl groups of up to 4 carbon atoms.
  • Aryl includes phenyl and naphthyl optionally substituted by one or more substituents selected from halo, C1-6 alkyl and C1-6 alkoxy.
  • Values for monocyclic heteroaryl include pyridyl, pyrimidyl, pyrazinyl, pyrryl, imidazolyl, thienyl, furanyl, oxazole or thiazole (all possible isomers). Bicyclic heteroaryl include benzofuranyl, benzothiophenyl, indolyl and indazolyl, quinolyl and isoquinolyl (all possible isomers).
  • Values for 3 to 8 membered heterocyclyl, include cyclic polymethylene interrupted by one or two of N, O or S, linked through C or N, for example N-linked piperidinyl or pyrrolidinyl.
      • Halo includes fluoro, chloro, bromo and iodo, preferably chloro.
      • L in formula (a) is favourably C—H, C—CH3, C—Cl or C—OCH3.
      • Q in formula (a) is favourably NR1 a.
      • R1 a is preferably hydrogen or a methyl or ethyl group.
      • R1 b is preferably methoxy.
      • R3 b is preferably amino.
      • R4 b is preferably halo.
      • R5 b is preferably hydrogen.
  • A substituent when halo is selected from fluoro, chloro, bromo and iodo. R4 a when halo is preferably iodo
  • Suitable examples of the X1—(CH2)x—X2 moiety include O—(CH2)2—O, O—(CH2)3—O, O—CH2—O, O—(CH2)2—NR, O—(CH2)2—S or O—CH2—CONR, wherein any of the methylene linkages are optionally mono- or di- substituted by C1-6 alkyl groups, such as methyl. Preferably X1—(CH2)2—X2 is O—(CH2)2—O.
  • Further suitable examples of X1—(CH2)x—X2 include O—(CH2)2—CH2, O—(CH2)3—CH2, O—CH2—CH2, or corresponding values wherein X1═X2═CH2, wherein any of the methylene linkages are optionally mono- or di-substituted by C1-6 alkyl groups, such as methyl. Preferably such X1—(CH2)2—X2 is O—(CH2)2—CH2.
      • R1 d is preferably hydrogen or amino.
      • R2 d is preferably hydrogen or halo.
      • R3 d is preferably hydrogen or halo.
      • R4 d and R5 d are often hydrogen. When R4 d or R5 d is C1-6 alkyl, it is often methyl.
      • R1 e is preferably CF3 or an ethyl group.
      • X5 is preferably N, C—H or C—OCH3;
      • R3 e is preferably hydrogen.
      • R4 e is preferably hydrogen or halo, such as iodo.
  • Suitable examples of X6-X7 when CR1 fR2 f—CR3 fR4 f include CH2—CH2 and CH═CH. X6—X7 is preferably NRz—CO, however, such as NH—CO or NEt-CO.
      • Ra f is preferably hydrogen.
      • Rb f is preferably hydrogen or halo, such as iodo.
  • Values for A include —CH2—(CH2)r—CH2— wherein r is 0, 1 or 2; —CH2—CH═CH—; —C(CH3)═CH— or when Xg is CH or N, A may be —(CH2)2—CH═or —CH═CH—CH═. Other examples of A are as described in the aforementioned patent publications.
  • R1 g and R2 g are often hydrogen or R1 g and R2 9 are gem-dimethyl. r is often 1.
  • R3 g is preferably hydrogen.
  • R4 g is preferably hydrogen or halo, such as fluoro.
  • Other suitable values of X are as described in PCT/GB93/020208, PCT/EP93/02808, PCT/EP93/02775, PCT/EP93/02809, PCT/GB93/02130, PCT/GB94/00172 (all in the name of SmithKline Beecham plc).
  • When Z is of sub-formula (h), n1 is preferably 2, 3 or 4 when the azacycle is attached at the nitrogen atom and n1 is preferably 1 when the azacycle is attached at a carbon atom, such as the 4-position when q is 2.
  • When Z is of sub-formula (j), n2 is preferably such that the number of carbon atoms between the ester or amide linkage is from 2 to 4 carbon atoms.
  • Suitable values for p and m include p=m=1; p=0, m=1, p=1, m=2 p=2, m=1.
  • When Z is of sub-formula (k), n3 is preferably 2, 3 or 4.
  • R8 and R9 are preferably both alkyl, especially one of R8 and R9 is C4 larger alkyl.
  • Specific values of Z of particular interest are as follows:
    Figure US20060094702A1-20060504-C00004
  • The invention also provides novel compounds within formula (I) with side chains (i), (ii), (iii), (iv), (v), (vi) or (vii). In a further aspect, the piperidine ring in (i), (ii) or (iii) may be replaced by pyrrolidinyl or azetidinyl, and/or the N-substituent in (i) or (ii) may be replaced by C3 or larger alkyl or optionally substituted benzyl.
  • In an alternative aspect, the N-substituent in formula (i) or (ii) may be replaced by (CH2)nR4 as defined in formula (I) of EPA 501322 and in relation to the specific examples of EP-A-501322, or it may be replaced by a substituent as as defined in formula (I) and in relation to the specific examples of in PCT/EP93/03054 (SmithKline Beecham plc).
  • The pharmaceutically acceptable salts of the compounds of the formula (I) include acid addition salts with conventional acids such as hydrochloric, hydrobromic, boric, phosphoric, sulphuric acids and pharmaceutically acceptable organic acids such as acetic, tartaric, maleic, citric, succinic, benzoic, ascorbic, methanesulphonic, a-keto glutaric, a-glycerophosphoric, and glucose-1-phosphoric acids.
  • Examples of pharmaceutically acceptable salts include quaternary derivatives of the compounds of formula (I) such as the compounds quaternised by compounds Rx-T wherein Rx is C1-6 alkyl, phenyl-C1-6 alkyl or C5-7 cycloalkyl, and T is a radical corresponding to an anion of an acid. Suitable examples of Rx include methyl, ethyl and n- and iso-propyl; and benzyl and phenethyl. Suitable examples of T include halide such as chloride, bromide and iodide.
  • Examples of pharmaceutically acceptable salts also include internal salts such as N-oxides.
  • The compounds of the formula (I), their pharmaceutically acceptable salts, (including quaternary derivatives and N-oxides) may also form pharmaceutically acceptable solvates, such as hydrates, which are included wherever a compound of formula (I) or a salt thereof is herein referred to.
  • The compounds of formula (I) may be prepared by conventional methods for forming ketones, such as those described in EP-A-242973 (Glaxo Group Limited) and EP-A-387431 (Beecham Group plc).
  • Reference is made to the aforemetioned patent publications in the name of Beecham Group plc in respect of intermediates containing X and Z moieties.
  • The compounds of the present invention are 5-HT4 receptor antagonists and it is thus believed may generally be used in the treatment or prophylaxis of gastrointestinal disorders, cardiovascular disorders and CNS disorders.
  • They are of potential interest in the treatment of irritable bowel syndrome (IBS), in particular the diarrhoea aspects of IBS, i.e., these compounds block the ability of 5-HT to stimulate gut motility via activation of enteric neurones. In animal models of IBS, this can be conveniently measured as a reduction of the rate of defaecation. They are also of potential use in the treatment of urinary incontinence which is often associated with IBS.
  • They may also be of potential use in other gastrointestinal disorders, such as those associated with upper gut motility, and as antiemetics. In particular, they are of potential use in the treatment of the nausea and gastric symptoms of gastro-esophageal reflux disease and dyspepsia. Antiemetic activity is determined in known animal models of cytotoxic-agent/radiation induced emesis.
  • Specific cardiac 5-HT4 receptor antagonists which prevent atrial fibrillation and other atrial arrhythmias associated with 5-HT, would also be expected to reduce occurrence of stroke (see A. J. Kaumann 1990, Naumyn-Schmiedeberg's Arch. Pharmacol. 342, 619-622, for appropriate animal test method).
  • Anxiolytic activity is likely to be effected via the hippocampus (Dumuis et al 1988, Mol Pharmacol., 34, 880-887). Activity can be demonstrated in standard animal models, the social interaction test and the X-maze test.
  • Migraine sufferers often undergo situations of anxiety and emotional stress that precede the appearance of headache (Sachs, 1985, Migraine, Pan Books, London). It has also been observed that during and within 48 hours of a migraine attack, cyclic AMP levels are considerably increased in the cerebrospinal fluid (Welch et al., 1976, Headache 16, 160-167). It is believed that a migraine, including the prodomal phase and the associated increased levels of cyclic AMP are related to stimulation of 5-HT4 receptors, and hence that administration of a 5-HT4 antagonist is of potential benefit in relieving a migraine attack.
  • Other CNS disorders of interest include schizophrenia, Parkinson's disease and Huntingdon's chorea.
  • The invention also provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • Such compositions are prepared by admixture and are usually adapted for enteral such as oral, nasal or rectal, or parenteral administration, and as such may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, nasal sprays, suppositories, injectable and infusable solutions or suspensions. Orally administrable compositions are preferred, since they are more convenient for general use.
  • Tablets and capsules for oral administration are usually presented in a unit dose, and contain conventional excipients such as binding agents, fillers, diluents, tabletting agents, lubricants, disintegrants, colourants, flavourings, and wetting agents. The tablets may be coated according to well known methods in the art, for example with an enteric coating.
  • Suitable fillers for use include cellulose, mannitol, lactose and other similar agents. Suitable disintegrants include starch, polyvinylpolypyrrolidone and starch derivatives such as sodium starch glycollate. Suitable lubricants include, for example, magnesium stearate.
  • Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulphate. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.
  • Oral liquid preparations are usually in the form of aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs or are presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and flavouring or colouring agents.
  • The oral compositions may be prepared by conventional methods of blending, filling or tabletting. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are, of course, conventional in the art.
  • For parenteral administration, fluid unit dose forms are prepared containing a compound of the present invention and a sterile vehicle. The compound, depending on the vehicle and the concentration, can be either suspended or dissolved. Parenteral solutions are normally prepared by dissolving the compound in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are also dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum.
  • Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilised by exposure of ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound of the invention.
  • The invention further provides a method of treatment or prophylaxis of irritable bowel syndrome, dyspepsia, atrial arrhythmias and stroke, anxiety and/or migraine in mammals, such as humans, which comprises the administration of an effective amount of a compound of the formula (I) or a pharmaceutically acceptable salt thereof.
  • An amount effective to treat the disorders hereinbefore described depends on the relative efficacies of the compounds of the invention, the nature and severity of the disorder being treated and the weight of the mammal. However, a unit dose for a 70 kg adult will normally contain 0.05 to 1000 mg for example 0.5 to 500 mg, of the compound of the invention. Unit doses may be administered once or more than once a day, for example, 2, 3 or 4 times a day, more usually 1 to 3 times a day, that is in the range of approximately 0.0001 to 50 mg/kg/day, more usually 0.0002 to 25 mg/kg/day.
  • No adverse toxicological effects are indicated within the aforementioned dosage ranges.
  • The invention also provides a compound of formula (1) or a pharmaceutically acceptable salt thereof for use as an active therapeutic substance, in particular for use in the treatment of irritable bowel syndrome, gastro-oesophageal reflux disease, dyspepsia, atrial arrhythmias and stroke, anxiety and/or migraine.
  • The following Examples illustrates the preparation of compounds of formula (I), and the following Descriptions relate to the preparation of intermediates.
  • A preferred compound corresponds to any example, but wherein there is an amino substituent in the 4-position and a chloro substituent in the 5-position of the benzoic acid nucleus depicted in formula (I).
    • EXAMPLE 1 [X=a), L=CH, Q=NCH3, R3 a and R4 a=H,Z=]
  • a) 1-(1-Methyl-1H-indol-3-yl)-3-(4-pyridyl)-propan-1-one
  • The product from Description 1, (0.190 g, 0.540 mmol) was dissolved in trifluoroacetic acid (7 ml), and heated to reflux with stirring. After 4 h, the reaction mixture was allowed to cool, was diluted with water and treated with aq. potassium carbonate until basic. The aqueous suspension was then extracted with CHCl3 (2×). The combined organic layers were then dried (Na2SO4), and evaporated under reduced pressure to give an orange solid, which was dried in vacuo (0.101 g). The solid was then dissolved in EtOH (15 ml), treated with 10% PdC, and hydrogenated at atmospheric pressure. After 16 h, the reaction mixture was filtered through kieselguhr, evaporated under reduced pressure, and dried in vacuo to give the title compound as a colourless oil (0.100 g, 69%).
  • 1H NMR (250 MHz, CDCl3), δ 8.50 (d, 2H), 8.35 (m, 1H), 7.70 (s, 1H), 7.40-7.10 (m, 5H), 3.84 (s, 3H), 3.15 (m, 4H).
  • b) 1-(1-Methyl-1H-indol-3-yl)-3-(1-butylpiperidin-4-yl)propan-1-one
  • The product from a) above (0.100 g, 0.379 mmol) was dissolved in acetone (4 ml), and treated with 1-bromobutane (0.122 ml, 1.137 mmol) and the mixture was heated to reflux with stirring. After 3 h, a further amount of 1-bromobutane (0.122 ml, 1.137 mmol) was added and reflux continued overnight. More 1-bromobutane was then added (0.244 ml, 2.274 mmol), and reflux continued for a further 8 h. The reaction mixture was then evaporated under reduced pressure and the residue dissolved in ethanol (10 ml) and acetic acid (0.5 ml). Platinum (IV) oxide (0.03 g) was then added and the mixture hydrogenated at atmospheric pressure. After 16 h, the reaction mixture was filtered through kieselguhr and the filtrate evaporated under reduced pressure and dried in vacuo. The product was then purified by silica-gel chromatography (CH2Cl2/10% MeOH as eluant) to give the title compound as a pale yellow oil (0.052 g, 43%) which was converted to its oxalate salt m.pt 124-126 °C. (oxalate salt)
  • 1 H NMR (200 MHz, CDCl3)-free base-δ 8.38 (m, 14H), 7.80 (s, 1H), 7.32 (m, 3H), 3.90 (s, 3H), 3.20 (d, 2H), 2.90 (t, 2H), 2.58 (t, 2H), 2.28 (t, 2H), 1.90-1.50 (m, 8H), 1.35 (m, 3H), 0.95 (t, 3H).
    • EXAMPLE 2 [X=(g), Xg═O, A=(CH2)3, R1 g, R2 g, R3 g, R4 g═H; Z=(i)]
  • a) 1-(3,4-Dihydro-2H-[-1,3]oxazino[3,2a]indol-10-yl)-3-hydroxy-3-(4-pyridyl)propan-1-one
  • 1.6M n-Butyllithium (1.67 ml, 2.67 mmol) was added to dry THF (12 ml), containing diisopropylamine (0.374 ml, 2.67 mmol) under argon at 0° C. with stirring. After 15 minutes, the mixture was cooled to −78° C., and the product from Description 2 (0.420 g, 2.43 mmol) in dry THF (8 ml) was added slowly. The resulting mixture was then left at −78° C. for 1 h, before pyridine-4-carboxaldehyde (0.232 ml, 2.43 mmol) was added. After a further 1 h, at −78° C., the reaction mixture was allowed to warm to room temperature, whereupon the reaction mixture was quenched with aq. ammonium chloride. The reaction mixture was then partitioned between ethyl acetate and water. The aqueous layer was then extracted with ethyl acetate (1×), and the combined organic layers were dried (Na2SO4), and evaporated under reduced pressure to give a pale brown solid, which was purified by silica-gel chromatography (CH2Cl2/5%MeOH as eluant) to give the title compound as an off white solid (0.246 g, 31%).
  • 1H NMR (200 MHz, CDCl3) δ 8.54 (d, 2H), 8.27 (d, 1H), 7.40-7.00 (m, 5H), 5.30 (dd, 1H), 4.88 (s, 1H), 4.50 (t, 2H), 4.10 (t, 2H), 3.30 (dd, 1H), 3.05 (dd, 1H), 2.33 (m, 2H).
  • b) E-1-(3,4-Dihydro-2H-[1,3]oxazino[3,2a]indol-3-yl)-3(4-pyridyl)-prop-2-en-1-one
  • The product from a) (0.220 g, 6.83 mmol) was dissolved in trifluoroacetic acid (20 ml), and heated to reflux with stirring. After 4 h, the reaction mixture was allowed to cool and was evaporated under reduced pressure. The residue was then treated with aq. sodium bicarbonate and the resultant yellow suspension was extracted with CHCl3 (3×). The combined organic layers were then dried (Na2SO4), and evaporated under reduced pressure to give a yellow solid. The solid was purified by silica-gel chromatography (CH2Cl2/5% MeOH as eluant) to give the title compound as a yellow solid (0.190 g, 92%).
  • 1H NMR (200 MHz, CDCl3) δ 8.60 (d, 2H), 8.45 (d, 1H), 7.80 (d, 1H), 7.62 (d, 1H), 7.40 (d, 2H), 7.35-7.00 (m, 3H), 4.60 (t, 2H), 4.03 (t, 2H), 2.48-2.30 (m, 2H).
  • c) 1-(3,4-Dihydro-2H-[1,3]oxazino[3,2a]indol-10-yl)-3(4-pyridyl)propan-1-one
  • The product from b) (0.190 g, 0.625 mmol) was dissolved in ethanol (40 ml) and hydrogenated at atmospheric pressure in the presence of 10% PdC (0.05 g). After 17 h, the reaction mixture was filtered through kieselguhr, and the filtrate evaporated under reduced pressure and dried in vacuo to give a colourless oil, which was purified by silica-gel chromatography (CH2Cl2/5% MeOH as eluant) to give the title compound as a pale yellow solid (0.130 g, 68%).
  • 1H NMR (200 MHz, CDCl3) δ 8.48 (d, 2H), 8.32 (d, 1H), 7.32-7.05 (m, 5H), 4.50 (t, 2H), 4.08 (t, 2H), 3.20-2.95 (m, 4H), 2.35 (m, 2H).
  • d) 1-(3,4-Dihydro-2H[1,3]oxazino[3,2a]indol-10-yl)-3 (1-butyl-4-piperidinyl)propan-1-one
  • The product from c) (0.120 g, 0.392 mmol) was dissolved in acetone (4 ml), and treated with 1-bromobutane (0.127 ml, 1.18 mmol) and heated to reflux with stirring. After 2 h, and 5 h, further amounts of 1-bromobutane were added, (0.127 ml, 1.18 mmol) and (0.254 ml, 2.36 mmol) respectively. Reflux was continued for a further 15 h. The reaction mixture was then evaporated under reduced pressure, and dried in vacuo. The off white solid obtained was then redissolved in ethanol (20 ml) containing acetic acid (0.5 ml); platinum (IV) oxide (0.03 g) was then added and the mixture was hydrogenated at atmospheric pressure. After 24 h, the reaction mixture was filtered through kieselguhr, and the filtrate evaporated under reduced pressure and dried in vacuo. The reaction mixture was then purified by silica-gel chromatography (CH2Cl2/10% MeOH as eluant) to give the title compound as an off white solid (0.053 g, 37%), which was converted to its oxalate salt. m.pt 156-159° C. (oxalate salt)
  • 1H NMR (200 MHz, CDCl3)-free base-δ 8.32 (d, 1H), 7.30-7.05 (m, 3H), 4.55 (t, 2H), 4.12 (t, 2H), 3.20 (d, 2H), 2.88 (t, 2H), 2.60 (t, 2H), 2.45-2.18 (m, 4H), 1.95-1.50 (m, 9H), 1.35 (m, 2H), 0.97 (t, 3H).
    • Description 1 (Intermediate for Example 1)
  • a) 3-Acetyl-1-methyl-1H-indole
  • 3-Acetyl-1H-indole (4.00 g, 0.025 mol) was dissolved in dry THF (100 ml), and treated with 80% sodium hydride (0.794 g, 0.0263 mol) with stirring under Ar. After 0.5h, methyl iodide (2.36 ml, 0.038 mol) was added. After 20h, the reaction mixture was evaporated under reduced pressure and the residue partitioned between ethyl acetate and water. The organic layer was then dried (Na2SO4), and evaporated under reduced pressure to give the title compound as a pale brown oil which crystallised on standing (4.20 g, 97%).
  • 1H NMR (250 MHz, CDCl3), δ 8.40 (m, 1H), 7.70 (s, 1H), 7.30 (m, 3H), 3.85 (s, 3H), 2.52 (s, 3H).
  • b) 1-(1-Methyl-1H-indol-3-yl)-3-(4-pyridyl)-3-trimethylsilyloxypropan-1-one
  • 1.6M n-Butyllithium (1.19 ml, 1.90 mmol) was added to dry THF (10 ml) containing diisopropylamine (0.266 ml, 1.90 mmol) under Ar at 0° C. After 15 mins, the mixture was cooled to −78° C., and 3-acetyl-1-methyl-1H-indole (0.300 g, 1.73 mmol) in dry THF (5 ml) was added slowly. The resulting mixture was left at −78° C. for 1h, before pyridine-4-carboxaldehyde (0.165 ml, 1.73 mmol) was added. The reaction mixture was then left at −78° C. for 1h, before being allowed to warm to 0° C., whereupon chlorotrimethylsilane (0.439 ml, 3.46 mmol) was added. The mixture was then allowed to warm to room temp and stirred for 1 h, before being evaporated under reduced pressure and partitioned between dichloromethane and water. The organic layer was then dried (Na2SO4) and evaporated under reduced pressure to give a pale yellow solid which was purified by silica-gel chromatography (EtOAc as eluant) to give the title compound as a yellow solid (0.300 g, 51%).
  • 1 H NMR (270 MHz, CDCl3) δ 8.54 (d, 2H), 8.40 (m, 1H), 7.63 (s, 1H), 7.38 (d, 2H), 7.30 (m, 3H), 5.45 (dd, 1H), 3.80 (s, 3H), 3.30 (dd, 1H), 2.92 (dd, 1H), 0.0 (s, 9H).
    • Description 2 (Intermediate for Example 2)
  • a) N-Methoxy-N-methyl-(1H-indol-3-yl)-carboxamide Indole-3-carboxylic acid (2.50 g, 0.0155 mol) was suspended in dichloromethane (60 ml) and treated with oxalyl chloride (1.62 ml, 0.0186 mol), followed by a drop of dry DMF. The reaction mixture was then stirred at room temperature overnight, before being evaporated under reduced pressure and dried in vacuo. The product was then redissolved in dichloromethane (50 ml) and added slowly to a solution of N,O-dimethylhydroxylamine hydrochloride (1.59 g, 0.0163 mol) in dichloromethane (50 ml) containing triethylamine (4.53 ml, 0.0326 mol) under argon. The resultant mixture was then stirred at room temperature for 2 h, before being washed with water, followed by aq. NaHCO3. The organic layer was then dried (Na2SO4), evaporated under reduced pressure and dried in vacuo to yield the title compound as white solid (2.46 g, 78%).
  • 1H NMR (200 MHz, CDCl3) δ 9.00 (s, 1H), 8.40 (m, 1H), 7.90 (d, 1H), 7.40 (m, 1H), 7.25 (m, 2H), 3.70 (s, 3H), 3.40 (s, 3H).
  • b) N-Methoxy-N-Methyl-(3,4-dihydro-2H[1,3oxazino[3,2a]indol-10-yl]carboxamide
  • The product from a) (2.42 g, 0.0119 mol) was suspended in chloroform (95 ml), with stirring, and treated with triethylamine (1.65 ml, 0.0119 mol) and 3-bromopropanol (2.15 ml, 0.0238 mol), followed by N-chlorosuccinimide (1.85 g, 0.0139 mol). The mixture was then stirred at room temperature for 1.5 h. 1M HCl in diethyl ether (0.333 ml, 0.333 mmol), was then added. After 5 minutes, and 10 minutes, further quantities of 1M HCl (0.333 ml) were added. Upon addition of the last quantity of HCl, the temperature was observed to rise to 34° C. After a further 0.5 h, the reaction mixture was washed with 10% Na2CO3. The organic layer was then dried (Na2SO4), evaporated under reduced pressure and dried in vacuo, before being redissolved in acetone (70 ml) and treated with anhydrous K2CO3 (3.07 g, 0.0222 mol) with stirring. The reaction mixture was then stirred overnight, filtered, and the filtrate evaporated under reduced pressure to give a brown oil, which was dried in vacuo, and then purified by silica-gel chromatography (EtOAc as eluant) to give the title compound as a colourless oil which crystallised on standing (2.60 g, 84%).
  • 1 H NMR (200 MHz, CDCl3) δ 7.75 (m, 1H), 7.25-7.10 (m, 3H), 4.50 (t, 2H), 4.12 (t, 2H), 3.70 (s, 3H), 3.32 (s, 3H), 2.35 (m, 2H).
  • c) 10-Acetyl-3,4-dihydro-2H-[1,3]oxazino[3,2]indole
  • The product from b) (0.99 g, 3.81 mmol) was dissolved in dry THF, cooled to 0° C., and treated with 3.0M methylmagnesium bromide in diethyl ether (1.41 ml, 4.24 mmol) under argon, with stirring. After 20 minutes at 0° C., the reaction mixture was allowed to warm to room temperature, and after 2 h, a further quantity of 3.0M methylmagnesium bromide (1.41 ml, 4.24 mmol) was added. The reaction mixture was then stirred for a further 2 h, before aq. ammonium chloride was added. The reaction mixture was then partitioned between EtOAc and water. The aqueous layer was then extracted with EtOAc, and the combined organic layers were dried (Na2SO4) and evaporated under reduced pressure to give a red solid. Recrystalisation of the solid from EtOAc gave the title compound as a pale pink solid (0.275 g, 34%). A further quantity of the title compound was obtained by silica-gel chromatography (pentane:EtOAc, 1:2 as eluant) of the filtrate from the recrystallisation, to give the title compound as a cream solid (0.152 g, 18%).
  • 1 H NMR (250 MHz, CDCl3) δ 8.32 (d, 1H), 7.30-7.00 (m, 3H), 4.52 (t, 2H), 4.05 (t, 2H), 2.50 (s, 3H), 2.35 (m, 2H).
  • 5-HT4 Receptor Antagonist Activity
  • 1) Guinea Pig Colon
  • Male guinea-pigs, weighing 250-400 g are used. Longitudinal muscle-myenteric plexus preparations, approximately 3 cm long, are obtained from the distal colon region. These are suspended under a 0.5 g load in isolated tissue baths containing Krebs solution bubbled with 5% CO2 in O2 and maintained at 37° C. In all experiments, the Krebs solution also contains methiothepin 10-7M and granisetron 10-6M to block effects at 5-HT1, 5-HT2 and 5-HT3 receptors.
  • After construction of a simple concentration-response curve with 5-HT, using 30 s contact times and a 15 min dosing cycle, a concentration of 5-HT is selected so as to obtain a contraction of the muscle approximately 40-70% maximum(10-9M approx). The tissue is then alternately dosed every 15 min with this concentration of 5-HT and then with an approximately equi-effective concentration of the nicotine receptor stimulant, dimethylphenylpiperazinium (DMPP). After obtaining consistent responses to both 5-HT and DMPP, increasing concentrations of a putative 5-HT4 receptor antagonist are then added to the bathing solution. The effects of this compound are then determined as a percentage reduction of the contractions evoked by 5-HT or by DMPP. From this data, pIC50 values are determined, being defined as the -log concentration of antagonist which reduces the contraction by 50%. A compound which reduces the response to 5-HT but not to DMPP is believed to act as a 5-HT4 receptor antagonist.
  • The compound of Example 1 had a pIC50 of 6.8.

Claims (6)

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof:

X—CO—CH2-Z   (I)
wherein
X is of formula (d):
Figure US20060094702A1-20060504-C00005
X1—(CH2)x—X2 forms a 5-7 membered ring wherein X1 is O or S; X2 is O, S, —CH2—, NR or NRCO wherein R is hydrogen or C1-6 alkyl; and
x is 1, 2 or 3;
R1 d is hydrogen, amino, halo, C1-6 alkyl, hydroxy or C1-6 alkoxy;
R2 d is hydrogen, halo, C1-6 alkyl, C1-6 alkoxy, nitro, amino or C1-6 alkylthio;
R3 d is hydrogen, halo, C1-6 alkyl, C1-6 alkoxy or amino;
R4 d and R5 d are independently hydrogen or C1-6 alkyl;
Z is of sub-formula (h), (j) or (k):
Figure US20060094702A1-20060504-C00006
wherein
n1 is 1, 2, 3 or 4; n2is 0, 1, 2, 3 or 4; n3is 2, 3, 4 or 5;
q is 0, 1, 2 or 3; p is 0, 1 or 2; m is 0, 1 or 2;
R5 is hydrogen, C1-12 alkyl, aralkyl or R5 is (CH2)z—R10 wherein z is 2 or 3 and R10 is selected from cyano, hydroxyl, C1-6 alkoxy, phenoxy, C(O)C1-6 alkyl, COC6H5, —CONR11R12, NR11COR12, SO2NR11R12 or NR11SO2R12 wherein R11 and R12 are hydrogen or C1-6 alkyl; or R5 is straight or branched chain alkylene of chain length 1-6 carbon atoms terminally substituted by aryl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 5 or 6 membered monocyclic heteroaryl or 9 or 10 membered fused bicyclic heteroaryl linked through carbon, C2-7 alkoxycarbonyl, or secondary or tertiary hydroxy substituted C1-6 alkyl; ; and
R6, R7 and R8 are independently hydrogen or C1-6 alkyl; and
R9 is hydrogen or C1-10 alkyl;
having 5-HT4 receptor antagonist activity.
2. A compound according to claim 1 wherein: X1—(CH2)x—X2 is O—(CH2)2—O, O—(CH2)3—O, O—CH2—O, O—(CH2)2—NR, O—(CH2)2—S, O—CH2—CONR, O—(CH2)2—CH2, O—(CH2)3—CH2, or O—CH2—CH2, wherein any of the methylene linkages are optionally mono- or di- substituted by C1-6 alkyl groups;
R1 d is hydrogen or amino;
R2 d is hydrogen or halo;
R3 d is hydrogen or halo.
3. A pharmaceutical composition comprising a compound according to claim 1, and a pharmaceutically acceptable carrier.
4. A method of treating a gastrointestinal disorder selected from the group consisting of irritable bowel syndrome, emesis, urinary incontinence associated with irritable bowel syndrome, dyspepsia and gastro-oesophageal reflux disease which comprises administering a compound according to claim 1.
5. A method of treating atrial arrhythmia or stroke which comprises administering a compound according to claim 1.
6. A method of treating a CNS disorder selected from the group consisting of migraine, schizophrenia, Parkinson's disease, Huntingdon's chorea and anxiety which comprises administering a compound according to claim 1.
US11/304,110 1993-05-22 2005-12-15 5-HT4 receptor antagonists Abandoned US20060094702A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/304,110 US20060094702A1 (en) 1993-05-22 2005-12-15 5-HT4 receptor antagonists

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GB939310582A GB9310582D0 (en) 1993-05-22 1993-05-22 Pharmaceuticals
GB9310582.3 1993-05-22
PCT/EP1994/001583 WO1994027987A1 (en) 1993-05-22 1994-05-16 5-ht4 receptor antagonists
US08/553,390 US5741801A (en) 1993-05-22 1994-05-16 5-HT4 receptor antagonist
US1313598A 1998-01-26 1998-01-26
US09/939,914 US20020019386A1 (en) 1993-05-22 2001-08-27 5-HT4 receptor antagonists
US10/317,159 US20030139389A1 (en) 1993-05-22 2002-12-11 5-HT4 receptor antagonists
US11/304,110 US20060094702A1 (en) 1993-05-22 2005-12-15 5-HT4 receptor antagonists

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/317,159 Continuation US20030139389A1 (en) 1993-05-22 2002-12-11 5-HT4 receptor antagonists

Publications (1)

Publication Number Publication Date
US20060094702A1 true US20060094702A1 (en) 2006-05-04

Family

ID=10735954

Family Applications (6)

Application Number Title Priority Date Filing Date
US08/553,390 Expired - Fee Related US5741801A (en) 1993-05-22 1994-05-16 5-HT4 receptor antagonist
US09/013,385 Expired - Fee Related US6114329A (en) 1993-05-22 1998-01-26 5-HT4 receptor antagonists useful in the treatment of gastroinstestinal, cardiovascular and CNS disorders
US09/013,138 Expired - Fee Related US5872134A (en) 1993-05-22 1998-01-26 5-HT4 receptor antagonists
US09/939,914 Abandoned US20020019386A1 (en) 1993-05-22 2001-08-27 5-HT4 receptor antagonists
US10/317,159 Abandoned US20030139389A1 (en) 1993-05-22 2002-12-11 5-HT4 receptor antagonists
US11/304,110 Abandoned US20060094702A1 (en) 1993-05-22 2005-12-15 5-HT4 receptor antagonists

Family Applications Before (5)

Application Number Title Priority Date Filing Date
US08/553,390 Expired - Fee Related US5741801A (en) 1993-05-22 1994-05-16 5-HT4 receptor antagonist
US09/013,385 Expired - Fee Related US6114329A (en) 1993-05-22 1998-01-26 5-HT4 receptor antagonists useful in the treatment of gastroinstestinal, cardiovascular and CNS disorders
US09/013,138 Expired - Fee Related US5872134A (en) 1993-05-22 1998-01-26 5-HT4 receptor antagonists
US09/939,914 Abandoned US20020019386A1 (en) 1993-05-22 2001-08-27 5-HT4 receptor antagonists
US10/317,159 Abandoned US20030139389A1 (en) 1993-05-22 2002-12-11 5-HT4 receptor antagonists

Country Status (13)

Country Link
US (6) US5741801A (en)
EP (1) EP0699194B1 (en)
JP (1) JP3981406B2 (en)
CN (1) CN1126472A (en)
AT (1) ATE346850T1 (en)
AU (1) AU693449B2 (en)
CA (1) CA2163372A1 (en)
DE (1) DE69434888T2 (en)
ES (1) ES2277330T3 (en)
GB (1) GB9310582D0 (en)
NZ (1) NZ267099A (en)
WO (1) WO1994027987A1 (en)
ZA (1) ZA943493B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5852014A (en) * 1992-03-12 1998-12-22 Smithkline Beecham P.L.C. Condensed indole derivatives as 5HT4 -receptor antagonists
US5998409A (en) * 1992-03-12 1999-12-07 Smithkline Beecham Plc Condensed indole derivatives as 5HT4 -receptor antagonists
JPH08502283A (en) * 1992-10-16 1996-03-12 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 5-HT 4) Fused ring system N-alkylpiperidinyl-4-methylcarboxylic acid ester / amide for receptor antagonist
GB9310582D0 (en) * 1993-05-22 1993-07-07 Smithkline Beecham Plc Pharmaceuticals
US5654320A (en) * 1995-03-16 1997-08-05 Eli Lilly And Company Indazolecarboxamides
IL117438A (en) * 1995-03-16 2001-12-23 Lilly Co Eli Indazolecarboxamides, their preparation and pharmaceutical compositions containing them
ATE250931T1 (en) * 1996-02-15 2003-10-15 Janssen Pharmaceutica Nv USE OF 5-HT4 ANTAGONISTS TO OVERCOME GASTROINTESTINAL DAMAGE CAUSED BY SEROTONIN REUPtake INHIBITORS
US6069152A (en) * 1997-10-07 2000-05-30 Eli Lilly And Company 5-HT4 agonists and antagonists
CA2340952C (en) * 1998-09-10 2009-12-08 F. Hoffmann-La Roche Ag Dihydrobenzodioxine carboxamide and ketone derivatives as 5-ht4 receptor antagonists
GB9820294D0 (en) * 1998-09-17 1998-11-11 Smithkline Beecham Plc Pharmaceuticals
US20030220907A1 (en) * 2001-08-24 2003-11-27 Sorensen Jens Erik Organizing ideas accumulated in a computer database
GB0211230D0 (en) * 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
TW200533348A (en) * 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
US7728006B2 (en) * 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
TWI351282B (en) 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US8309575B2 (en) 2004-04-07 2012-11-13 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
EP1807423B1 (en) * 2004-11-05 2009-05-20 Theravance, Inc. Quinolinone-carboxamide compounds
EP1807422B1 (en) * 2004-11-05 2009-09-02 Theravance, Inc. 5-ht4 receptor agonist compounds
JP5159317B2 (en) * 2004-12-22 2013-03-06 セラヴァンス， インコーポレーテッド Indazole-carboxamide compounds
AU2006218603A1 (en) * 2005-03-02 2006-09-08 Theravance, Inc. Quinolinone compounds as 5-HT4 receptor agonists
WO2010065743A2 (en) * 2008-12-03 2010-06-10 Nanotherapeutics, Inc. Bicyclic compounds and methods of making and using same
EP2990140B1 (en) * 2014-08-27 2019-01-02 SLM Solutions Group AG Method for manufcaturing a component containing an iron alloy material, component and iron alloy material.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763458A (en) * 1993-05-26 1998-06-09 Syntex (U.S.A.) Inc. 1-phenylalkanone 5-HT4 receptor ligands
US6172062B1 (en) * 1998-09-10 2001-01-09 Syntex (Usa) Llc Dihydrobenzodioxine carboxamide and ketone derivatives

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3462440A (en) * 1965-12-03 1969-08-19 American Home Prod 1,4-bis(2-indol-3-ylethyl)piperidines
FR2334358A1 (en) * 1975-12-12 1977-07-08 Sogeras NEW DRUGS DERIVED FROM INDOLE
FR2560873B1 (en) * 1984-03-09 1986-09-26 Rhone Poulenc Sante DRUGS BASED ON PIPERIDINE DERIVATIVES, NOVEL PIPERIDINE DERIVATIVES AND THEIR PREPARATION METHODS
DK134687A (en) * 1986-03-17 1987-09-18 Glaxo Group Ltd indole derivatives
EP0387431A1 (en) * 1989-03-14 1990-09-19 Beecham Group Plc Imidazole derivatives, process for their preparation and their pharmaceutical use
GB9103862D0 (en) * 1991-02-25 1991-04-10 Glaxo Group Ltd Chemical compounds
EP0596933A1 (en) * 1991-08-03 1994-05-18 Smithkline Beecham Plc 5-ht4 receptor antagonists
JPH06510283A (en) * 1991-08-20 1994-11-17 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 5-HT4 receptor antagonist
JP3294611B2 (en) * 1991-09-12 2002-06-24 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 5-HT4 receptor antagonist
EP0609278A1 (en) * 1991-10-24 1994-08-10 Smithkline Beecham Plc Imidazopyridines and indolizines as 5-ht 4 antagonists
GB9204565D0 (en) * 1992-03-03 1992-04-15 Smithkline Beecham Plc Pharmaceuticals
JP2831467B2 (en) * 1992-03-12 1998-12-02 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 5HT (4)-Condensed indole derivatives as receptor antagonists
US5852014A (en) * 1992-03-12 1998-12-22 Smithkline Beecham P.L.C. Condensed indole derivatives as 5HT4 -receptor antagonists
TW226019B (en) * 1992-03-23 1994-07-01 Sankyo Co
GB9310582D0 (en) * 1993-05-22 1993-07-07 Smithkline Beecham Plc Pharmaceuticals

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763458A (en) * 1993-05-26 1998-06-09 Syntex (U.S.A.) Inc. 1-phenylalkanone 5-HT4 receptor ligands
US6172062B1 (en) * 1998-09-10 2001-01-09 Syntex (Usa) Llc Dihydrobenzodioxine carboxamide and ketone derivatives

Also Published As

Publication number Publication date
DE69434888D1 (en) 2007-01-11
WO1994027987A1 (en) 1994-12-08
AU693449B2 (en) 1998-07-02
NZ267099A (en) 1997-12-19
JP3981406B2 (en) 2007-09-26
US5872134A (en) 1999-02-16
US6114329A (en) 2000-09-05
CN1126472A (en) 1996-07-10
DE69434888T2 (en) 2007-06-14
ATE346850T1 (en) 2006-12-15
US5741801A (en) 1998-04-21
JPH08510266A (en) 1996-10-29
US20020019386A1 (en) 2002-02-14
ZA943493B (en) 1995-11-20
AU6928394A (en) 1994-12-20
CA2163372A1 (en) 1994-12-08
ES2277330T3 (en) 2007-07-01
EP0699194B1 (en) 2006-11-29
GB9310582D0 (en) 1993-07-07
EP0699194A1 (en) 1996-03-06
US20030139389A1 (en) 2003-07-24

Similar Documents

Publication Publication Date Title
US5741801A (en) 5-HT4 receptor antagonist
US5705498A (en) Piperidine derivatives as 5-HT4 receptor antagonists
US5696129A (en) 5-HT4 antagonists
US5708174A (en) Heterocyclic-esters or -amides used as 5-HT4 receptor antagonists
US5726187A (en) N-alkylpiperidinyl-4-methyl carboxylic esters/amides of condensed ring systems as 5-HT4 receptor antagonists
US5620992A (en) Heteroaryl compounds used as pharmaceuticals
WO1993008187A1 (en) Imidazopyridines and indolizines as 5-ht4 antagonists
US5705509A (en) Tricyclic heterocyclic compounds as 5-HT4 receptor antagonists
WO1994029298A1 (en) 8-amino-7-chloro-1,4-benzodioxan-5-carboxylic acid, -1-butyl-4-piperidinyl ester as a 5-ht4-receptor antagonist
EP0712406B1 (en) Condensed indole derivatives as 5-ht 4-receptor antagonists
WO1994019344A1 (en) Amide compounds with pharmacological activity

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载